Does semaglutide protect your heart?

People taking Ozempic or Wegovy often ask whether semaglutide does anything for the heart beyond weight loss. A September 2025 systematic review and meta-analysis published in the European Journal of Medical Research provides the most comprehensive pooled answer to date, drawing on 10 randomised controlled trials and 22,937 patients with overweight or obesity.1 The short answer: semaglutide meaningfully reduces several cardiovascular risks - but the protection is not uniform, and some of the results need independent confirmation.

What did the meta-analysis measure?

Researchers Wu et al. searched for all published RCTs comparing semaglutide to placebo or active control in adults with overweight or obesity, then pooled the cardiovascular and renal outcome data.1 The 10 included trials enrolled a combined 22,937 participants - 12,200 assigned to semaglutide and 10,737 to control - with participant ages ranging from 46 to 69 years. No funding was received for the analysis, and the authors declared no competing interests.

The primary outcomes were arrhythmias (including atrial fibrillation and sinus node dysfunction), major adverse cardiovascular events (acute MI, angina, stroke), and renal outcomes. The results differed substantially by endpoint.

What were the cardiovascular findings?

Semaglutide produced statistically significant reductions in four cardiovascular endpoints.

Source: Wu R et al., European Journal of Medical Research, September 2, 2025.1 RR = risk ratio; CI = confidence interval. Values below 1.0 indicate lower risk with semaglutide.

The strongest result is for acute MI, where the confidence interval is entirely below 1.0 and reasonably narrow (0.60-0.85), indicating a robust 28% relative risk reduction. The angina pectoris result is similar in direction and strength.

The atrial fibrillation result is meaningful - a 21% reduction - but the upper bound of the confidence interval reaches 0.99, sitting right at the statistical threshold. This does not make the finding invalid, but it does mean clinicians and patients should treat it as promising evidence rather than a settled conclusion. The sinus node dysfunction result has a very wide confidence interval (0.19-1.00) and cannot be interpreted as reliable.

"The heart attack result is robust. The AFib result is real but close to the boundary - watch for larger trials."

Who benefits most from semaglutide's heart effects?

The meta-analysis found that the cardiovascular benefits of semaglutide were not evenly distributed by age or treatment duration. Patients over 60 years old showed more pronounced reductions in cardiovascular events. Patients treated for more than 52 weeks also showed stronger effects than those on shorter courses.1

This pattern is clinically important. Most people who start semaglutide for weight management are not over 60 and may not stay on the drug for more than a year. The patients most likely to see the clearest heart benefit are those with pre-existing cardiovascular risk factors who remain on therapy long-term - a population that includes many people using Ozempic for type 2 diabetes management.

What about kidney protection?

The 2025 meta-analysis found no statistically significant effect of semaglutide on renal outcomes in this dataset.1 This is not a signal that semaglutide is harmful to the kidneys - it is a signal that this particular analysis, which was designed primarily to examine arrhythmias and cardiovascular events, did not detect a kidney benefit.

Dedicated kidney outcome trials tell a different story. The FLOW trial - a purpose-built randomised trial in patients with type 2 diabetes and chronic kidney disease - showed semaglutide reduced major kidney events by 24%, major cardiovascular events by 18%, and all-cause mortality by 20% versus placebo.2 For patients with pre-existing kidney disease, the FLOW data is a more relevant source than the 2025 meta-analysis, which was not designed with kidney endpoints as a primary focus.

How does this fit with what we already knew?

The FDA approved semaglutide (as Ozempic) with a cardiovascular risk-reduction label for people with type 2 diabetes and established cardiovascular disease, based primarily on the SUSTAIN-6 and SELECT trials.3 The 2025 meta-analysis adds to that evidence by examining a broader population (overweight and obesity, not only T2D) and by specifically quantifying arrhythmia outcomes, which have not historically been a primary endpoint in the major trials.

The AFib finding is the most novel part of this paper. Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting an estimated 37 million people worldwide, and obesity is a well-established risk factor.1 If the 21% risk reduction for AFib holds up in larger dedicated trials, it would represent a clinically significant additional benefit for the millions of people taking semaglutide for weight management who were not previously considered cardiovascular patients.

What this does not mean

A relative risk reduction of 28% for MI sounds large, but it applies to an already-low absolute rate of events in these trials. The absolute risk reduction for any individual patient will depend heavily on their baseline cardiovascular risk. Semaglutide is not a substitute for established cardiovascular medications - it is an addition to them, for the right patient.

The analysis also pools trials conducted in patients with overweight or obesity specifically, so these numbers may not transfer directly to patients taking semaglutide for type 2 diabetes control alone, where body weight and cardiovascular risk profiles differ.

In one sentence: a 2025 meta-analysis of 22,937 patients confirms semaglutide meaningfully cuts heart attack and angina risk, shows a promising but boundary-level reduction in atrial fibrillation, and found no kidney effect - though dedicated kidney trials in CKD patients tell a more positive story on that endpoint.